Cahill Wealth Management LLC lifted its stake in Sensus Healthcare, Inc. (NASDAQ:SRTS – Free Report) by 12.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 73,859 shares of the company’s stock after acquiring an additional 8,309 shares during the period. Cahill Wealth Management LLC owned 0.45% of Sensus Healthcare worth $233,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also made changes to their positions in the stock. Truvestments Capital LLC raised its position in Sensus Healthcare by 47.2% in the second quarter. Truvestments Capital LLC now owns 35,676 shares of the company’s stock worth $112,000 after acquiring an additional 11,446 shares in the last quarter. Victory Capital Management Inc. raised its holdings in shares of Sensus Healthcare by 330.6% in the 2nd quarter. Victory Capital Management Inc. now owns 28,024 shares of the company’s stock worth $88,000 after purchasing an additional 21,516 shares in the last quarter. Denali Advisors LLC lifted its stake in Sensus Healthcare by 414.5% during the second quarter. Denali Advisors LLC now owns 39,100 shares of the company’s stock valued at $123,000 after purchasing an additional 31,500 shares during the last quarter. Rockefeller Capital Management L.P. boosted its holdings in Sensus Healthcare by 214.3% during the first quarter. Rockefeller Capital Management L.P. now owns 22,000 shares of the company’s stock worth $114,000 after buying an additional 15,000 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in Sensus Healthcare in the first quarter worth approximately $62,000. 20.56% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on SRTS shares. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Sensus Healthcare in a research note on Monday, November 13th. TheStreet downgraded Sensus Healthcare from a “c” rating to a “d+” rating in a report on Friday, November 10th.
Insider Activity at Sensus Healthcare
In related news, CEO Joseph C. Sardano purchased 10,000 shares of Sensus Healthcare stock in a transaction dated Thursday, September 14th. The stock was acquired at an average cost of $2.88 per share, with a total value of $28,800.00. Following the completion of the transaction, the chief executive officer now directly owns 1,175,293 shares of the company’s stock, valued at $3,384,843.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.10% of the stock is owned by insiders.
Sensus Healthcare Stock Performance
Shares of NASDAQ:SRTS traded up $0.06 during mid-day trading on Tuesday, hitting $2.13. The stock had a trading volume of 12,905 shares, compared to its average volume of 162,913. The company’s 50 day moving average is $2.42 and its 200-day moving average is $2.82. Sensus Healthcare, Inc. has a 12-month low of $1.79 and a 12-month high of $9.62. The company has a market cap of $34.89 million, a PE ratio of -34.50 and a beta of 0.63.
Sensus Healthcare (NASDAQ:SRTS – Get Free Report) last announced its earnings results on Thursday, November 9th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.08). The firm had revenue of $3.90 million for the quarter, compared to analyst estimates of $6.04 million. Sensus Healthcare had a negative net margin of 3.58% and a negative return on equity of 1.93%. On average, equities research analysts predict that Sensus Healthcare, Inc. will post -0.17 EPS for the current fiscal year.
Sensus Healthcare Profile
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
- Five stocks we like better than Sensus Healthcare
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Zoom Video Communications: A tech phoenix ready to rise
- What Are Dividend Challengers?
- The only two airline stocks worth buying: One is a Goldman pick
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Ride the momentum: Apparel stocks soaring at 52-week highs
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.